Florbetaben
Progressive Supranuclear Palsy (PSP)
Molecular NeuroImagingSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Progressive Supranuclear Palsy (PSP) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IOFLUPANE GE Healthcare | Phase 3 | BB |
FLORTAUCIPIR Molecular NeuroImaging | Phase 1 | CC |
[18f]mni-815 Molecular NeuroImaging | Early Phase 1 | CC |
[18F]ABBV-965i Invicro | Early Phase 1 | C |
[18F]ABBV-964i Invicro | Early Phase 1 | C |
Leucine Washington University School of Medicine | D |
Same molecule, other indications
Florbetaben is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →